Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro
Hulda R. Jónsdóttir, Denise Siegrist, Thomas Julien, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 113058-113058
Open Access | Times Cited: 22

Showing 22 citing articles:

Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”
M. Veronica Dioverti, Sonsoles Salto‐Alejandre, Ghady Haidar
Current Transplantation Reports (2022) Vol. 9, Iss. 4, pp. 209-218
Open Access | Times Cited: 56
Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table
Mitra Ranjbar, Ali Rahimi, Zeinab Baghernejadan, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109325-109325
Open Access | Times Cited: 44
Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
Davide Marangoni, Roberta Maria Antonello, Marco Coppi, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 53-56
Open Access | Times Cited: 27
Air-Liquid interface cultures to model drug delivery through the mucociliary epithelial barrier
Rhianna E. Lee, Boris Reidel, Mark Nelson, et al.
Advanced Drug Delivery Reviews (2023) Vol. 198, pp. 114866-114866
Open Access | Times Cited: 21
Host-targeted antivirals against SARS-CoV-2 in clinical development - prospect or disappointment?
André Schreiber, Stephan Ludwig
Antiviral Research (2025) Vol. 235, pp. 106101-106101
Open Access
Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
M. Veronica Dioverti, Zeinab El Boghdadly, Zainab Shahid, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 12, pp. 810-821
Open Access | Times Cited: 24
The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
Lina Kamal, Ahmed Ramadan, Suha A. Farraj, et al.
Saudi Pharmaceutical Journal (2022) Vol. 30, Iss. 5, pp. 508-518
Open Access | Times Cited: 20
A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapy
Norein Sakander, Ajaz Ahmed, Mahir Bhardwaj, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107379-107379
Closed Access | Times Cited: 3
Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
Rana Abdelnabi, Piet Maes, Steven De Jonghe, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Disposable and Sensitive Electrochemical Determination of Molnupiravir at a Pencil Graphite Electrode (PGE) by Differential Pulse Voltammetry (DPV)
Serkan Karakaya, Yusuf Dilgin
Analytical Letters (2023) Vol. 57, Iss. 5, pp. 783-796
Closed Access | Times Cited: 8
Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma
Timofey Komarov, P. K. Karnakova, O. A. Archakova, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2356-2356
Open Access | Times Cited: 8
Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns
Paul-Rémi Petit, Franck Touret, Jean‐Sélim Driouich, et al.
Heliyon (2024) Vol. 10, Iss. 10, pp. e30862-e30862
Open Access | Times Cited: 2
Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection
Wujun Chen, Yingchun Shao, Xiaojin Peng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 11
The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model
Thuc Nguyen Dan, Rana Abdelnabi, Bernadett Boda, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
Thuc Nguyen Dan, Rana Abdelnabi, Bernadett Boda, et al.
Antiviral Research (2024) Vol. 231, pp. 105994-105994
Open Access | Times Cited: 1
Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology
Yalan Zhou, Huizhen Wang, Yang Li, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8257-8257
Open Access | Times Cited: 6
Mapping the Lipid Signatures in COVID-19 Infection: Diagnostic and Therapeutic Solutions
Aishi Dasgupta, Shon Gangai, Rishikesh Narayan, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14411-14433
Closed Access | Times Cited: 3
A Fast Scoring of Human Primary Respiratory Epithelia Grown at Air–Liquid Interface (ALI) to Assess Epithelial Morphology in Research and Personalized Medicine Settings
Christopher T. Lutsch, Longhua Feng, Ana Gómez Hohn, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 109-109
Open Access
Nanobody against SARS-CoV-2 non-structural protein Nsp9 inhibits viral replication in human airway epithelia
Tomáš Venit, Jérémy Blavier, Sibusiso B. Maseko, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 3, pp. 102304-102304
Open Access
Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia
Denise Siegrist, Hulda R. Jónsdóttir, Mendy Bouveret, et al.
Pharmaceutics (2024) Vol. 16, Iss. 10, pp. 1262-1262
Open Access
Transport of Designed Ankyrin Repeat Proteins through reconstituted human bronchial epithelia and protection against SARS-CoV-2
Lisa Künzi, Sarah Ryter, Andreas Cornelius, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Combination of the parent analogue of Remdesivir (GS-441524) and Molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
Rana Abdelnabi, Piet Maes, Steven De Jonghe, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top